Another group of antagonists at mGlu5, termed selective negative allosteric modulators (NAMs), meaning that they bind to a site that differs from the glutamate binding site and thereby modify the receptor’s configuration, have also been investigated as anti-migraine agents. The gene discussed is GRM5; the disease is migraine disorder.